News
CLRBZ
0.1190
0.00%
0.0000
Cellectar Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Cellectar Biosciences Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 61 cents per share. The mean expectation of four analysts was for a loss of 57 cents. The average analyst rating on the shares is "strong buy"
Reuters · 03/27 13:31
BUZZ-U.S. STOCKS ON THE MOVE-Akero Therapeutics, Vista Outdoor, Sea
Dow Jones Industrial Average down 0.20% on Monday. S&P 500 and Nasdaq's record-closing highs in the prior session. Akero Therapeutics, Vista Outdoor, Sea are among the day's top stocks on thedaq. The U.S. Markets are set to open on a down day.
Reuters · 03/04 19:01
BUZZ-U.S. STOCKS ON THE MOVE-Super Micro, Decker, Rumble
Wall Street's main indexes dipped on Monday after the S&P 500 and the Nasdaq's record-closing highs in the prior session. The Dow Jones Industrial Average was down 0.24% at 38,994.68. The Nasdaq Composite was also down on the day. Super Micro, Decker, Rumble among the stocks on the move.
Reuters · 03/04 16:08
BUZZ-Cellectar Biosciences up on positive data from early-stage cancer therapy trial
Cellectar Biosciences up on positive data from early-stage cancer therapy trial. Shares of drug developer rise 7.6% to $4.52 premarket. Co says its experimental cancer therapy in combination with radiation therapy was safe and tolerated in the study.
Reuters · 03/04 14:02
BUZZ-U.S. STOCKS ON THE MOVE-Halozyme, Scorpio Tankers
Wall Street's main indexes fell on Tuesday after mixed earnings from Morgan Stanley and Goldman Sachs. Dow Jones Industrial Average was down 0.61% and the S&P 500 and Nasdaq Composite were also down. Boeing and Apple were among the biggest decliners, with declines in both companies.
Reuters · 01/16 18:54
BUZZ-Cellectar rises on positive data for pancreatic cancer treatment
Cellectar Biosciences rises on positive data for pancreatic cancer treatment. Shares of Cellectar rise 4.6% to $3.67. Drug developer expects to start early-stage human trials for the drug later this year or early next year. Stock rose 62% in 2023.
Reuters · 01/16 17:50
BUZZ-U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
Tech-laden Nasdaq jumped more than 1% to a one-week high on Monday. Dow slipped to a fresh two-week low as Boeing shares tanked following the grounding of some jets. Top three S&P 500 percentage gainers: Baxter International, American Airlines Group.
Reuters · 01/08 19:09
BUZZ-U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
U.S. Blue-chip index Dow slipped to a fresh two-week low on Monday. Boeing shares fell following the grounding of some its jets. The rebound in megacaps and chip stocks supported the other U.s. Stock indexes. The Dow Jones Industrial Average was down 0.13% at 37,416.29.
Reuters · 01/08 15:57
BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Coinbase, Ambrx Biopharma
Dow e-minis poised for a lower open on Monday. Boeing shares tumble following grounding of some of its jets. Other major U.S. Indexes eyed a subdued open. Top three NYSE percentage gainers: Surf Air Mobility, Unifi. The top two Nasdaq percentage losers: Solo Brands and Alibaba.
Reuters · 01/08 14:30
UPDATE 1-Cellectar's blood cancer therapy succeeds in late-stage study
Cellectar's therapy for rare form of blood cancer succeeds in late-stage study. 75.6% of patients with Waldenstrom's macroglobulinemia saw cancer decrease in size or disappear after treatment. Company's shares up 45% in premarket trading.
Reuters · 01/08 12:18
BUZZ-Cellectar Biosciences up on succeeding blood cancer therapy studies
Shares of Cellectar Biosciences up 55.3% at $4.2 premarket - among biggest pct gainer across US stock exchanges. Company says its blood cancer therapy met the main goal in succeeding study. Study showed 75.6% overall response rate for the therapy.
Reuters · 01/08 12:08
Cellectar's blood cancer therapy succeeds in trial
Cellectar's blood cancer therapy succeeds in trial. Therapy met the main goal when tested in patients who received two prior lines of therapy. Cellectar Biosciences' therapy is for a type of blood cancer called Waldenstrom's macroglobulinemia.
Reuters · 01/08 11:40
Cellectar Biosciences Inc expected to post a loss of 43 cents a share - Earnings Preview
Reuters · 10/31/2023 19:00
BUZZ-U.S. STOCKS ON THE MOVE-Knowles, RE/MAX Holdings, BioCryst Pharma
Reuters · 09/18/2023 18:30
BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, Lyft, natgas firms
Reuters · 09/18/2023 16:28
BUZZ-Cellectar jumps on EMA's 'Priority Medicines' tag for blood cancer drug
Reuters · 09/18/2023 13:10
Cellectar Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Reuters · 08/14/2023 13:32
BRIEF-Cellectar Biosciences - Pediatric High-Grade Glioma Trial To Initiate In Q3
Reuters · 06/12/2023 13:59
More
Webull provides a variety of real-time CLRBZ stock news. You can receive the latest news about CELLECTAR BIOSC through multiple platforms. This information may help you make smarter investment decisions.
About CLRBZ
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).